Navigation Links
Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority
Date:2/28/2011

ortance of harmonization between the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) to reduce the cost of clinical trials, especially for makers of therapies used to treat small rare disease populations, was another key issue analyzed by the participants. Clinical trials for rare disease therapies can cost more than 75 million euro ($100 million). As a result, Dr. Hammarstrom said some necessary clinical trials will never be done. "This means that certain types of therapies will be unavailable on both sides of the Atlantic," he said.

In addition, according to Peter Turner, Europe and the US are seldom aligned on clinical trial design. "Quite often we have to design a European trial and then a US trial because of requirements differing across the Atlantic," Mr. Turner explained. Yann Le Cam noted that EURORDIS has been working toward a solution by partnering with the EMA and the FDA on a retrospective analysis of orphan drug designations versus applications to better understand potential common approaches to new therapies. "There were many more commonalities than differences," Mr. Le Cam said. "Ninety-two percent of the decisions were the same."  

AvailabilityThere is a further complication in that the availability of treatments for rare diseases differs from country to country. According to Peter Saltonstall, if a therapy has been used on patients for period of time in Europe and the European safety and efficacy standards have been demonstrated, it is important to find a way to apply that information within the U.S. market.  "There needs to be a way for patients to get the drugs and therapies more quickly," Mr. Saltonstall said.

Yann Le Cam pointed out that globally, 80-85% of people with rare diseases are treated with off-label drugs and therapies. "We should encourage the collection of data during off-label use, both on safety and efficacy. This would be good medical practice that can lead to better
'/>"/>

SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. intendiX - Communication by Thoughts: First Patient-Ready System on the Market
2. Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference
3. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
4. Safe and Secure TV Channel Expanding Programming and Revenue Agreements for 2011 with Pentagons Military News Channel and other Security Industry Leaders
5. Science advisor to the US EPA to speak to industry, academic leaders on sustainability innovations
6. InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbrietâ„¢ (Pirfenidone) in Europe
7. A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge
8. Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco
9. iPierian Expands Leadership Team With Experienced Business Development and Intellectual Property Executives
10. BioStorage Technologies Brings Together Industry Leaders for Global Sample Management Benchmarking Symposium
11. Medix Uses Globalpark to Glean Insights From Over 20,000 Opinion Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... report expects global cell isolation and expansion market to ... carefully analyzed data about the vital drivers, restraints, trends, ... Copy of Report @ http://bit.ly/1yUxy0T , According ... will keep witnessing growth at an impressive CAGR during ... by rapid technological advancements, government funding and investments, and ...
(Date:12/24/2014)... 2014 Vermillion, Inc. (Nasdaq:   VRML), ... announced today that investors including Oracle Investment Management, ... and several Vermillion directors have agreed to purchase ... common stock and warrants to purchase unregistered shares ... Under the terms of the ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... May 7 The Sixth Annual Healthcare Unbound Conference ... (TCBI), will feature the coming together of consumer and ... The Conference will take place at the ... 2009. Attendees will include a diverse representation of ...
... May 7 /PRNewswire-FirstCall/ -- Delcath Systems, Inc., ... technology company testing its proprietary Percutaneous Hepatic Perfusion (PHP(TM)) System ... that Eric D. Whitman, MD, Director of the Atlantic Melanoma ... will present at The 7th World Congress on Melanoma, to ...
... Parma Group has reacquired the,marketing rights to its own ... of the American pharmaceutical company Cornerstone; it will,be setting ... market. This presence in the USA will prepare the ... of respiratory illnesses. , The ...
Cached Biology Technology:Sixth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Chronic Care Management & Wellness Promotion 2Sixth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Chronic Care Management & Wellness Promotion 3Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma 2Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma 3The Chiesi Group Lands in the United States 2The Chiesi Group Lands in the United States 3
(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
(Date:12/5/2014)... 4, 2014 Increased emphasis on product ... new testing and inspection technologies. The convergence of ... a range of innovative test solutions. This trend ... Y, which is generally more inclined towards communication, ... development strategies of test equipment vendors will cater ...
(Date:11/21/2014)... 2014 According to a new ... (Video, RFID, Access Control, Intrusion Detection, Parking Management, Under ... Component Service Geography - Global Forecasts to 2020", published ... to be around $25 Billion in 2014 and is ... a CAGR of 8.69%. Browse 116 market ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... eggs in the nest of a magpie so that their ... their young are not raised together with other magpies. The ... by their foster parents are much lower, according to research ... Spain. The findings are published in Springer,s journal Behavioral ...
... time, large-scale information on the biochemical makeup of ... These molecules are used in research to help ... Making these data accessible to researchers worldwide increases ... NIH,s National Center for Advancing Translational ...
... Calif. , Dec. 11, 2013  DigitalPersona, Inc., ... today announced that the DigitalPersona ® FingerJet ... certified by the National Institute of Standards and ... program to meet the United States Government,s  Personal ...
Cached Biology News:Magpie parents know a baby cuckoo when they see one 2Gene-silencing data now publicly available to help scientists better understand disease 2Gene-silencing data now publicly available to help scientists better understand disease 3DigitalPersona FingerJet Recognition Engine Top Performer in Recent MINEX Testing 2
Antibodies were affinity purified using epitopes specific to Alpha4 immobilized on solid support....
PlusOne Acrylamide PAGE, 1 kg. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Gel Casting Chemicals....
Donor Horse Serum US Origin...
jub, ajuba homolog (Xenopus laevis)...
Biology Products: